Research Institute: John Curtin School of Medical Research, Australian National University
Amount granted: $2 million
Year granted: 2015
The grant has been used to establish the ACRF Department of Cancer Biology and Therapeutics at the ANU John Curtin School of Medical Research (JCSMR).
The ACRF funding will dramatically transform the capabilities available to Professor Ross Hannan’s research and will enable discovery-based research and development of new compounds, drugs and diagnostic approaches for cancer treatment.
New high-technology equipment will allow screening of Australian natural product collections to rapidly identify bioactive components that may be helpful in developing new cancer treatments.
The Centre will utilise Australia’s Chemome (whole sets of small molecule natural products) and explore the existing collections for novel lead compounds that can be developed in to drugs for cancer therapy.
In contrast to the limited chemical diversity of synthetically developed drugs, the structural diversity available within the Australian Chemome is unparalleled.
The Facility was officially opened in February 2017.
What your donations have achieved
Cervical cancer vaccine
We gave initial seed funding to Professor Ian Frazer’s research into the cervical cancer (HPV). Over 150 million doses of vaccine have been delivered worldwide to date.
The pill that melts away cancer
Our long term support of cancer research at WEHI has led to a treatment that melts away certain advanced forms of chronic lymphocytic leukaemia. It has been approved for clinical use in the US, European Union and Australia and is being trialled for other types of cancer.
Personalised cancer diagnosis
In 2015, we awarded $10 million seed funding to an ambitious cancer proteome project that aims to provide each cancer patient a personalised treatment plan within 36 hours. This will improve treatment outcomes and help avoid unnecessary treatments.
Zero childhood cancer
We are one of the founding partners of the initiative that will tackle the most serious cases of infant, childhood and adolescent cancer in Australia. It is a key step towards the program vision of one day helping to cure 100% of children with cancer.